-
Je něco špatně v tomto záznamu ?
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review
S. Yaghoubi, AO. Zekiy, M. Krutova, M. Gholami, E. Kouhsari, M. Sholeh, Z. Ghafouri, F. Maleki
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, přehledy
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- antibakteriální látky * farmakologie terapeutické užití MeSH
- infekce získané v komunitě * mikrobiologie MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- minocyklin farmakokinetika terapeutické užití MeSH
- tigecyklin farmakologie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the treatment of polymicrobial infections caused by multidrug-resistant Gram-positive and Gram-negative pathogens. Tigecycline evades the main tetracycline resistance genetic mechanisms, such as tetracycline-specific efflux pump acquisition and ribosomal protection, via the addition of a glycyclamide moiety to the 9-position of minocycline. The use of the parenteral form of tigecycline is approved for complicated skin and skin structure infections (excluding diabetes foot infection), complicated intra-abdominal infections, and community-acquired bacterial pneumonia in adults. New evidence also suggests the effectiveness of tigecycline for the treatment of severe Clostridioides difficile infections. Tigecycline showed in vitro susceptibility to Coxiella spp., Rickettsia spp., and multidrug-resistant Neisseria gonnorrhoeae strains which indicate the possible use of tigecycline in the treatment of infections caused by these pathogens. Except for intrinsic, or often reported resistance in some Gram-negatives, tigecycline is effective against a wide range of multidrug-resistant nosocomial pathogens. Herein, we summarize the currently available data on tigecycline pharmacokinetics and pharmacodynamics, its mechanism of action, the epidemiology of tigecycline resistance, and its clinical effectiveness.
Department of Clinical Microbiology Iranshahr University of Medical Sciences Iranshahr Iran
Department of Microbiology Faculty of Medicine Iran University of Medical Sciences Tehran Iran
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025309
- 003
- CZ-PrNML
- 005
- 20221031100327.0
- 007
- ta
- 008
- 221017s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10096-020-04121-1 $2 doi
- 035 __
- $a (PubMed)33403565
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Yaghoubi, Sajad $u Department of Clinical Microbiology, Iranshahr University of Medical Sciences, Iranshahr, Iran
- 245 10
- $a Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review / $c S. Yaghoubi, AO. Zekiy, M. Krutova, M. Gholami, E. Kouhsari, M. Sholeh, Z. Ghafouri, F. Maleki
- 520 9_
- $a Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the treatment of polymicrobial infections caused by multidrug-resistant Gram-positive and Gram-negative pathogens. Tigecycline evades the main tetracycline resistance genetic mechanisms, such as tetracycline-specific efflux pump acquisition and ribosomal protection, via the addition of a glycyclamide moiety to the 9-position of minocycline. The use of the parenteral form of tigecycline is approved for complicated skin and skin structure infections (excluding diabetes foot infection), complicated intra-abdominal infections, and community-acquired bacterial pneumonia in adults. New evidence also suggests the effectiveness of tigecycline for the treatment of severe Clostridioides difficile infections. Tigecycline showed in vitro susceptibility to Coxiella spp., Rickettsia spp., and multidrug-resistant Neisseria gonnorrhoeae strains which indicate the possible use of tigecycline in the treatment of infections caused by these pathogens. Except for intrinsic, or often reported resistance in some Gram-negatives, tigecycline is effective against a wide range of multidrug-resistant nosocomial pathogens. Herein, we summarize the currently available data on tigecycline pharmacokinetics and pharmacodynamics, its mechanism of action, the epidemiology of tigecycline resistance, and its clinical effectiveness.
- 650 12
- $a antibakteriální látky $x farmakologie $x terapeutické užití $7 D000900
- 650 12
- $a infekce získané v komunitě $x mikrobiologie $7 D017714
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a minocyklin $x farmakokinetika $x terapeutické užití $7 D008911
- 650 _2
- $a tigecyklin $x farmakologie $7 D000078304
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Zekiy, Angelina Olegovna $u Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Russian Federation, Trubetskaya st., 8-2, 119991, Moscow, Russia
- 700 1_
- $a Krutova, Marcela $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Gholami, Mehrdad $u Department of Microbiology and Virology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
- 700 1_
- $a Kouhsari, Ebrahim $u Laboratory Sciences Research Center, Golestan University of Medical Sciences, P.O. Box 6939177143, Gorgan- Sari Road, Golestan Province, Gorgan, Iran. Ekouhsari1987@gmail.com $u Department of Laboratory Sciences, Faculty of Paramedicine, Golestan University of Medical Sciences, P.O. Box 6939177143, Gorgan- Sari Road, Golestan Province, Gorgan, Iran. Ekouhsari1987@gmail.com $1 https://orcid.org/http://orcid.org/0000000158936483
- 700 1_
- $a Sholeh, Mohammad $u Department of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Ghafouri, Zahra $u Department of Biochemistry, Biophysics and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
- 700 1_
- $a Maleki, Farajolah $u Department of Laboratory Sciences, School of Allied Medical Sciences, Ilam University of Medical sciences, Ilam, Iran. fmaleki88@yahoo.com
- 773 0_
- $w MED00001612 $t European journal of clinical microbiology & infectious diseases $x 1435-4373 $g Roč. 41, č. 7 (2022), s. 1003-1022
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33403565 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100325 $b ABA008
- 999 __
- $a ok $b bmc $g 1854825 $s 1176599
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 41 $c 7 $d 1003-1022 $e 20210105 $i 1435-4373 $m European journal of clinical microbiology & infectious diseases $n Eur J Clin Microbiol Infect Dis $x MED00001612
- LZP __
- $a Pubmed-20221017
